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AdenovirusTo date the Simian Virus 40 (SV40) is the only proven example of a virus that recruits the mechanism of RNA
trans-splicing to diversify its sequences and gene products. Thereby, two identical viral transcripts are efﬁciently
joined by homologous trans-splicing triggering the formation of a highly transforming 100 kDa super T antigen.
Sequences of other viruses including HIV-1 and the human adenovirus type 5 were reported to be involved in
heterologous trans-splicing towards cellular or viral sequences but the meaning of these events remains unclear.
We computationally and experimentally investigatedmolecular features associatedwith viral RNA trans-splicing
and identiﬁed a common pattern: Viral RNA trans-splicing occurs between strong cryptic or regular viral splice
sites and strong regular or cryptic splice sites of the trans-splice partner sequences. The majority of these splice
sites are supported by exonic splice enhancers. Splice sites that could compete with the trans-splicing sites for
cis-splice reactions are weaker or inexistent. Finally, all but one of the trans-splice reactions seem to be facilitated
by one or more complementary binding domains of 11 to 16 nucleotides in length which, however occur with a
statistical probability close to one for the given length of the involved sequences. The chimeric RNAs generated
via heterologous viral RNA trans-splicing either did not lead to fusion proteins or led to proteins of unknown
function. Our data suggest that distinct viral RNAs are highly susceptible to trans-splicing and that heterologous
viral trans-splicing, unlike homologous SV40 trans-splicing, represents a chance event.5 6777 5
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(http://creativecommons.org/licenses/by/4.0/).Viruses represent the smallest replicating specimens. Mammalian
viruses are mainly composed of the viral DNA or RNA genome, protein
coats protecting the genetic material, and in some cases lipid envelopes
surrounding the coat in the extracellular stage. The size of a viral particle
correlates with the size of its genome and for most viruses genome size
is a common theme. In order to express amaximumnumber of proteins,
viruses use an array of mechanisms which do not signiﬁcantly enlarge
the genomic size such as including the use of multiple promoters,
alternative open reading frames, translational frame shifting, stop
codon read-through, and alternative splicing. In the same sense, viruses
use virus-encoded small interfering (si)RNAs and antisense transcrip-
tion to regulate gene expression. Recently, we reported strong evidence
that viruses, i.e. the simian virus 40 (SV40), do also recruit the
mechanism of RNA trans-splicing to generate the full repertoire of
protein functions [1]. Inmammalian cells, RNA trans-splicing represents
a special form of alternative splicing in which two distinct RNA
transcripts are joined in trans with the help of the spliceosome leading720.
l@snafu.de (J. Eul),
of the ResearchNetwork ofto the formation of chimeric RNA molecules which can code for novel
functions or non-sense proteins. In the case of homologous SV40 RNA
trans-splicing, two identical early viral transcripts are joined triggering
the formation of a 100 kDa super tumour antigen (sT-ag). This
100 kDa protein was found to have superior cell transformation activity
as compared with the regular 94 kDa large T antigen (T-ag). The SV40
trans-splice reaction was described to be supported by various SV40-
intrinsic molecular helper functions which render this reaction highly
efﬁcient with about 50 to 70% of the viral pre-mRNA transcripts being
involved in trans-splicing. Sequences of other viruses including HIV-1
and the human adenovirus type 5 were reported to be involved in
trans-splicing as well [2,3]; however, these events have not been
investigated in depth and the question as to whether these reactions
represent chance events or are of relevance to the viruses remains
open.We used SV40 RNA trans-splicing as amodel and computationally
screened sequences reported to be involved in heterologous viral RNA
trans-splicing for common trans-splicing-associated molecular features
and signatures.
As opposed to conventional cis-splicing, the efﬁciency of trans-
splicing depends on the probability that two separate RNA precursor
molecules encounter each other in the nuclear compartment. This
probability increases with high sub-cellular RNA concentrations, e.g. in
consequence of productive viral RNA transcription and/or when theComputational and Structural Biotechnology. This is an open access article under theCCBY
Table 1
Analyses of splice sites and binding domains.
Virus Trans-splicing partner Potential
binding
domains
Trans-
splice
product
Name 
Splice information 
Name 
Splice information
Trans ss Trans ss
SV40 
exon 2 
5′cry 
U1 snRNA
6/9 bp, 14hb 
ESE 18 nts 
Sc 8.5/Sc
0.74 
Not 
relevant 
Alt cis ss  Alt cis ss
SV40 exon 2 3′reg
12/18 bp 
4 sites, 
6/6 bp, 13hb 
18 nts 
6.4/0.98 
5′reg (wt) 
5/9 bp, 12hb
10 nts 
8.7/0.73  
_______________ 
5′reg (mut)
a
4/9 bp, 10hb 
10 nts 
8.7/0.73 
10mer (22hb) 
13mer (31hb) 
Highly 
transforming 
100 kD
a
 super
T antigen 
Adeno-
virus type 
5 exon 2 
of major 
late 
transcript 
(MLT) 
3′reg 
U2AF65 
16/18 bp 
U2 snRNA 5 
sites, 
4/6 bp, 9hb 
Sc 13.3/Sc
1.00 
5′reg 
U1 snRNA 
8/9 bp, 19hb
ESE 8 nts 
10/0.99
v-abl Abelson 
murine leukaemia 
viral proto-
oncogene 
homolog 2 
transcript variant 
a (exon 1A) 
5′cry 
6/9 bp, 15hb 
11.8/0.95  
3′reg 
12/18 bp 
3 sites, 3/6 bp, 7hb 
8 nts 
8.5/0.74 
12mer (29hb) No fusion 
protein 
Zinc Finger 
protein (ZNF) 41 
exon 3 
5′reg 
9/9 bp, 22hb
9 nts 
12.8/0.98 
3′reg 
17/18 bp 
4 sites, 6/6 bp, 
12hb 
9 nts 
11mer (27hb) 
12mer (33hb) 
Fusion 
protein, 
function 
unknown 
Armadillo protein 
P0071 5 UTR 
5′cry 
6/9 bp, 14hb 
Not relevant 12mer (32hb) 
12mer (30hb) 
13mer (34hb) 
13mer (33hb) 
No fusion 
protein 
GTP-binding 
protein (RAB5) 
1st coding exon 
5′reg 
6/9 bp, 14hb 
7 nts 
Sequence 
information not 
found 
11mer (27hb) 
11mer (27hb) 
11mer (30hb) 
11mer (29hb) 
12mer (27hb) 
Fusion 
protein, 
function 
unknown 
GAPDH exons 
3, 5, 7 
Exon 3: 5′reg 
7/9 bp, 17hb 
12.4/0.99 
3′reg 
14/18 bp 
2 sites, 5/6 bp, 
11hb 
7.1/0.98 
12mer (33hb) 
12mer (30hb) 
12mer (32hb) 
12mer (31hb) 
13mer (35hb) 
13mer (35hb) 
13mer (33hb) 
15mer (40hb) 
16mer (44hb) 
Fusion 
protein, 
function 
unknown 
Exon 5: 5′reg 
8/9 bp, 18hb 
8 nts 
12.2/0.96 
3′reg 
12/18 bp 
2 sites, 5/6 bp, 
12hb 
5.9/0.98 
Exon 7: 5′reg 
4/9 bp, 10hb 
7 nts 
8.6/0.69 
3′reg 
12/18 bp 
3 sites, 3/6 bp, 6hb 
3.4/0.91 
β
9/9 bp, 22hb 
8 nts 
16.3/0.99 
5′reg 
12/18 bp 
2 sites, 3/6 bp, 7hb 
9.7/0.85 
12mer (34hb) 
13mer (38hb) 
13mer (33hb) 
Fusion 
protein, 
function 
unknown 
-Actin exon 3 5′reg 
T-plastin exon 1 5′reg ss 
6/9 bp, 14hb 
10.3/0.99 
3′reg 
14/18 bp 
9 sites, 4/6 bp, 9hb 
7 nts 
10.0/0.99 
11mer (24hb) 
11mer (30hb) 
11mer (28hb) 
Fusion 
protein, 
function 
unknown 
Interferon-
inducible gene 
(IFI)-54K, 1st
coding exon 
5′reg 
6/9 bp, 14hb 
11 nts 
11.3/1.00 
Sequence 
information not 
found 
None Fusion 
protein, 
function 
unknown 
HIV-1 nef 5′cry at aa 66
b
 
U1 snRNA 
6/9 bp,14hb
ESE 14 nts 
Sc 12.7/Sc  
0.74 
5′cry at aa 77
b
 
U1 snRNA 
6/9 bp,15hb 
ESE 14 nts 
Sc 12.3/Sc
0.78
Not 
relevant 
SV40 
T-antigen 
3′reg 
12/18 bp 
6 sites, 
6/6 bp,11hb 
18 nts 
6.5/0.98  
5′reg 
5/9 bp, 12hb 
10 nts
8.7/0.74 
11mer (28hb) Fusion
protein, 
function 
unknown 
KIAA1454 3′cry
No sequence 
information 
7.3 
5′cry 
No sequence 
information 
10mer (25hb) 
11mer (27hb) 
11mer (30hb) 
11mer (29hb) 
Not 
allocatable 
Cercopithecus 
aethiops
exons 1, 2, 3 
No splice 
junction 
information 
No splice junction 
information 
11mer (26hb) Not 
allocatable 
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the case of homologous including SV40 RNA trans-splicingwhich occurs
between two identical RNA precursors. Further, splicing in trans is
strongly enhanced between RNA precursors that harbour complemen-
tary antisense binding domains which can trigger intron-like bridging
between splice sites [4,5]. For homologous SV40 RNA trans-splicing
the following trans-splice helper functions were reported: 1. the early
SV40 transcript was found to harbour two binding domains (BDs) of
13 and 10 nucleotides (nts) in length respectively. 2. In addition, SV40
RNA trans-splicing was enhanced by mutational weakening of the T-
ag 5′ donor splice site (ss) which impaired cis-splicing in favour of the
alternative trans-splice reaction towards 3. a strong cryptic 5′ss within
a second pre-mRNAmolecule. In consequence of the T-ag 5′ssmutation,
only 4 instead of 5 nts of the 9 nt 5′ splice donor can base-pair to the U1
snRNA of the spliceosomal U1 snRNP, likely impeding its recruitment to
this 5′ss. The alternatively used cryptic 5′ss can bind with 6 of 9 nts to
the U1 snRNA and hence, represents a much stronger splice donor
site. 4. Finally, the alternative cryptic 5′ss was further strengthened by
an upstream purine-rich exonic splice enhancer (ESE). SV40 trans-
splicing was conﬁrmed by the systematic exclusion of alternative
mechanisms that might trigger the generation of the observed chimeric
RNA, such as direct coding from integrated rearranged SV40 DNA and
alternative RNA cis-splicing of a long pre-mRNA transcript that might
originate from genomic SV40 tandem integration, using southern
hybridization and PCR. The coincidence of various trans-splicing helper
functions led us to the conclusion that SV40 RNA trans-splicing is
certainly not a chance event but instead a mechanism that is intrinsic
to the virus leading to the diversiﬁcation of viral gene expression [6].
We used computational andmanual analyses to screen the adenovi-
rus type 5 exon 2 and the HIV-1 nef sequences as well as the reported
trans-splicing partner sequences for trans-splicing helper functions
deducted from the SV40 system. The adenoviral pre-mRNAwas report-
ed to splice in transwith various cellular host pre-mRNAs including the
v-abl Abelson murine leukaemia virus protooncogene homolog 2 tran-
script variant a, zinc ﬁnger protein 41 exon 3, armadillo protein P0071
5′UTR, GTP-binding protein (RAB5) 1st coding exon, GAPDH exons 3
to 7, β-actin exon 3, T-plastin exon 1, and 1st coding exon of the
interferon-inducible gene (IFI)-54K during the natural course of infec-
tion in human (U521MG, JEG3) cell lines [3]. Adenovirus type 5 is con-
sidered to be a non-integrating virus which excludes that the chimeric
RNAs are directly DNA coded or generated by alternative RNA cis-
splicing; thus the described fusion RNAs are most likely the product of
a trans-splice process. The HIV-1 nef mRNA was reported to splice in
trans with the SV40 pre-mRNA, KIAA1454, and Cercopithecus aethiops
genes 1, 2, and 3 in the cell lines CV1 and Cos7 [2]. The setup in these
HIV-1 experiments did not resemble the situation of a natural infection
and the HIV-1 nef sequence was either stably integrated into the host
cell genome to monitor trans-splicing with cellular targets or alterna-
tively microinjected as in vitro transcribed RNA together with an SV40
transcript. Thus, whilst hybrid RNAs formed with cellular sequences
could originate from mechanisms other than trans-splicing, the chime-
ric RNAs formed between HIV-1 nef and SV40 could only be generated
by RNA trans-splicing.
We (i) screened the abovementioned sequences for the presence of
potential antisense BDs, (ii) investigated the strength of the splice donor
and acceptor sites involved in RNA trans-splicing and (iii) alternativeNotes to Table 1:
aTrans-splicing is enhanced with A to C mutation in 5′ss of exon 1.bCry 5′ss at aa 66 trans-sp
C. aethiops.
ss = splice site, alt = alternative, reg = regular, cry = cryptic, hb = hydrogen bonds, and aa
U1 snRNA recognizes the 5’ss, consensus GUCCAUUCAUA...m3G; RNA-Match: YRGGURRGU
U2 snRNA recognizes the branch point sequence, consensus AUGAU_G; RNA-Match: URYU
U2AF65 recognizes the poly U/C stretch, consensus UUUUUU (U/C) CC(C/U) UUUUUUUCC  
ESE: purine A/G rich exonic splice enhancers (not indicated if not relevant)
Score predicted by the ASSP software (not indicated if not predicted) 
Score predicted by the BDGP SSP software (not indicated if not predicted)  cis-splicing options available to the respective sequences, and
(iv) searched for putative ESEs supporting either the trans-splice or reg-
ular cis-splice sites (Table 1).
As for the BDs we considered complementary sites of ten or more
consecutive nucleotides being suitable for the ﬁxation of two encoun-
tering RNAs under physiological conditions. For all but the adenovi-
rus::IFI-54K sequence pair we identiﬁed between one and nine BD
candidates. Each pair can recruit at least one 11mer BDwith the longest
interacting domains being 15 and 16 nts in length (adenovirus::
GAPDH). Though the identiﬁed BDs can support the trans-splice
reactions, many complementary BDs of 12 nts or shorter occur with a
probability close to one among sequences with a considerable length.
The expected number Nexp(LBD) of BDs of a given length LBD (nt) is in
good approximation given by Eq. (1)
Nexp LBDð Þ ¼ LALB=4LBD ð1Þ
with LA and LB as the respective lengths of the trans-splicing RNAs A and
B. The probability P to observe a BD of the length LBD is then given by
P ¼ Nexp LBDð Þ=Nobs LBDð Þ ð2Þ
with Nobs(LBD) as the actually observed frequency of BDs with the
length LBD. Accordingly, the majority if not all of viral pre/mRNAs have
the potential to bind towards mammalian including human pre-
mRNAs thus harbouring an important albeit not sufﬁcient molecular
feature for splicing in trans. The identiﬁed potential interactions
between viral sequences and their targets as listed in Table 1 are
summarised in Table 2.
The chance that two nuclear RNAs encounter and bind to each other
via BDs directly correlates with their nuclear abundance and high RNA
abundance has to considered an essential condition for trans-splicing.
Hence, it was not surprising that Kikumori and colleagues [3] detected
trans-splicing of adenoviral RNA with the highly abundant cellular
pre-mRNAs of β-actin and GAPDH when searching for it.
To investigate the strength of splice donor sites we considered the
number of consecutive base pairs and hydrogen bonds (hb) that can
be formed between the respective donors with the spliceosomal U1
snRNA. A very strong donor can form up to 9 bp with the U1 snRNA in-
cluding canonical Watson–Crick as well as wobble base pairs. To
assess the strength of splice acceptor sites we counted matches, base
pairs, and hydrogen bonds between the U2 snRNA and the branch
point consensus sequence as well as sequence matches with the poly
U/C stretch consensus sequence which is being recognised by the
spliceosomal factor U2AF65. In order to additionally consider the base
sequence, i.e. its compliance with the splice donor consensus sequence,
we used the algorithms Alternative Splice Site Predictor (ASSP) and
Splice Site Prediction (SSP) NNSPLICE 0.9 version to predict the strength
of each splice site reﬂected by a numeric score [7,8]. Accordingly, ASSP-
scores of 10 and above and SSP-scores close or equal to 1 have to be
considered high. Finally, we searched for purine (A/G)-rich sequences
of at least 7 nts or longer that might act as ESEs [9]. The molecular fea-
tures of the SV40 trans-splice reaction are included in the upper part
of Table 1 for reference. The involved strong cryptic splice donor has
no suitable downstream acceptor and splices in trans with the regular
SV40 splice acceptor site. Whilst the wild-type T-ag 5′ss efﬁcientlylices with SV40, KIAA1454, and C. aethiops; cry 5′ss at aa 77 trans-splices with SV40 and
= amino acid.
; GU = 100% invariant
RAY; UxA = 100% invariant, A: branch point 
Table 2
Possible base pairing between viral sequences and target RNAs.
Viral transcript Trans-splicing partner Potential binding domains
5′-virus-3′
3′-ts-partner-5′
SV40 exon 2 SV40 exon 2 10mer 5′-AGCUUUAAAU-3′
3′-UCGAAAUUUA-5′
13mer 5′-GUGGUUUGUCCAA-3′
3′-CAUCAAACAGGUU-5′
Adeno-virus type 5 exon 2 of major late
transcript (MLT)
v-abl Abelson murine leukaemia viral proto-oncogene homolog 2 transcript
variant a (exon 1A)
12mer 5′-GGAUAAAUGGAG-3′
3′-CCUAUUUACCUC-5′
Zinc ﬁnger protein (ZNF) 41 exon 3 11mer 5′-UUUUCCACAGC-3′
3′-AAAAGGUGUCG-5′
12mer 5′-CUGCAGCCAGGG-3′
3′-GACGUCGGUCCC-3′
Armadillo protein P0071 5 UTR 12mer 5′-GAGCUGGUGCUG-3′
3′-CUCGACCACGAC-5′
12mer 5′-CCAAAAACGAGG-3′
3′-GGUUUUUGCUCC-5′
13mer 5′-GUCAUCCCUGAGC-3′
3′-CAGUAGGGACUCG-5′
13mer 5′-GGUAUCCCACCAA-3′
3′-CCAUAGGGUGGUU-5′
GTP-binding protein (RAB5)
1st coding exon
11mer 5′-GUCAUCAAGAC-3′
3′-CAGUAGUUCUG-5′
11mer 5′-AGGACUUGCUU-3′
3′-UCCUGAACGAA-5′
11mer 5′-GCUAGGUCGGC-3′
3′-CGAUCCAGCCG-5′
11mer 5′-ACUCCUCCUCC-3′
3′-UGAGGAGGAGG-5′
12mer 5′-GGCAAUUUUUUA-3′
3′-CCGUUAAAAAAU-5′
GAPDH exons 3, 5, 7 12mer 5′-GGAAGGGGGUGG-3′
3′-CCUUCCCCCACC-5′
12mer 5′-AGGAGGACUUUG-3′
3′-UCCUCCUGAAAC-5′
12mer 5′-GGAGCAGAGAGC-3′
3′-CCUCGUCUCUCG-5′
12mer 5′-GGAUGCCCUUGA-3′
3′-CCUACGGGAACU-5′
13mer 5′-AGGCGCAGCAUCC-3′
3′-UCCGCGUCGUAGG-5′
13mer 5′-GGAGCGCAGGGUU-3′
3′-CCUCGCGUCCCAA-5′
13mer 5′-AGCUUCCCGUUCA-3′
3′-UCGAAGGGCAAGU-5′
15mer 5′-AAAGAGGGAGCGGGG-3′
3′-UUUCUCCCUCGCCCC-5′
16mer 5′-GGCGCUGCAGGAAGGG-3′
3′-CCGCGACGUCCUUCCC-5′
β-Actin exon 3 12mer 5′-CGGCGGUGGUGG-3′
3′-GCCGCCACCACC-5′
13mer 5′-UCCCCGCGGCGCG-3′
3′-AGGGGCGCCGCGC-5′
13mer 5′-UGAGCUGCGAGAA-3′
3′-ACUCGACGCUCUU-5′
T-plastin exon 1 11mer 5′-AACAAAAAGAU-3′
3′-UUGUUUUUCUA-5′
11mer 5′-CUCAGCUCCCC-3′
3′-GAGUCGAGGGG-5′
11mer 5′-GCCUUUGGGAA-3′
3′-CGGAAACCCUU-5′
Interferon-inducible gene (IFI)-54K, 1st coding exon – –
HIV-1 nef SV40 T-antigen 11mer 5′-AAGCAGCUGCU′3′
3′-UUCGUCGACGA-5′
KIAA1454 10mer 5′-CCACUGCUUA-3′
3′-GGUGACGAAU-5′
11mer 5′-UUCAUCACGUG-3′
3′-AAGUAGUGCAC-5′
11mer 5′-UGGGGUGGGAG-3′
3′-ACCCCACCCUC-5′
11mer 5′-GUGAGCCUGCA-3′
3′-CACUCGGACGU-5′
C. aethiops exons 1, 2, 3 11mer 5′-GAAGUGUUAGA-3′
3′-CUUCACAAUCU-5′
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strongly enhanced by mutational weakening of the T-ag 5′ donor ss. In
the case of the adenoviral transcript, a strong regular viral splice accep-
tor trans-spliceswith a variety ofmostly strong splice donor siteswithin
cellular pre-mRNAs. The corresponding regular cellular cis-splice accep-
tor sites are mostly weak and the viral cis-splice donor site that belongs
to the trans-splicing acceptor was assigned a lower score as well. In the
case of HIV-1 nef two alternative strong cryptic splice donors were de-
scribed to trans-splice with either SV40 RNA or two cellular mRNAs.
These cryptic donor sites have no corresponding HIV-1 nef acceptor
sites and the recruited SV40 acceptor represents a rather strong ss.
In summary, our data point towards a general pattern associated
with viral RNA trans-splicing which is schematically depicted in Fig. 1.
Accordingly, a strong viral cryptic or regular donor or acceptor ss splices
in trans with a rather strong regular or cryptic acceptor or donor
site. Notably, splice sites that could compete with the trans-splicing
sites by cis-splicing within the respective transcripts mostly are weaker
or inexistent. As expected, the majority of splice sites involved in trans-
splicing are supported by ESEs which can be identiﬁed in proximity of
many mammalian splice sites.
To experimentally investigate our hypothesis of ss selection/
preference in RNA trans-splicingwe set up an artiﬁcial test system com-
prising amini-gene, composed of three exonic segments (E1 to E3) joint
by two introns (I1 and I2), and two trans-splicing RNAs, one for 5′ and
one for 3′ exon replacement harbouring exons E1* or E3* respectively
(Fig. 2). Whilst I1 harbours a very strong donor (D1) and an acceptor
ss (A1) of medium strength, I2 was ﬂanked by strong donor (D2) and
strong acceptor (A2). Both trans-splicing RNAs were equipped with
strong donor (D) or acceptor (A) sites, which can be considered cryptic
splice sites since partnering cis-splice sites are not available, and BDs
guiding the trans-splicing sequences to the respective 5′ or 3′ terminal
intron. Consequently, the 5' or 3' splice sites of the trans-splicing RNAs
could choose either of the available acceptor or donor splice sites,
though one would expect that the target splice sites in proximity toFig. 1. Schematic illustration of a trans-splicing reaction between a viral pre/mRNA and an inte
with a rather strong regular splice donor (SDr), cryptic exonic splice donor (SDe) or cryptic intr
mostly areweaker or inexistent. b, In the case of theHIV-nef RNA one of two possible strong cry
cellular target. a and b:One ormore potential binding domains (BDs) of 11nts or longer can supp
the two strands has to partly turn around as indicated by the crossing arrows.WD:weak donor
splice enhancer.the binding site is preferred [10]. HepG2 cells were co-transfected
with plasmids expressing the mini-gene and one of the trans-splicing
RNAs, total RNA was isolated 24 h post transfection, and trans-spliced
RNAs were quantiﬁed using real-time reverse transcriptase PCR (rtRT-
PCR) and the beta-actin mRNA as internal standard. For both trans-
splicing RNAs, the fold change values indicate that alternative trans-
splicing towards the more distant target ss was favoured over the ex-
pected trans-splicing with the respective proximal ss. In detail, D-to-
A2 trans-splicing between the very strong donor D and the strong ac-
ceptor A2 was favoured (2.2-fold) over D-to-A1 trans-splicing from D
to the weak acceptor A1; similarly, D1-to-A trans-splicing between the
very strong donor D1 and the very strong acceptor A was favoured
(7.2-fold) over D2-to-A trans-splicing between strong donor D2,
which was a weaker donor than D1, and A. Notably, the alternative
cis-splice partner ss D2 or A1 of the favoured trans-splice target sites
A2 and D1 were weaker than partner sites D1 or A2 of the disfavoured
trans-splice target sites A1 or D2, respectively. By qualitative agarose
gel electrophoresis and by monitoring the melting proﬁle of the rtRT-
PCR products we excluded that longer products such as E1*/E2/E3 or
E1/E2/E3* were generated and co-detected during the quantiﬁcation
of distal E1*/E3 or E1/E3* exon joining. These data support our model
of ss selection during RNA trans-splicing indicating that (i) stronger tar-
get splice sites are favoured overweaker sites (ii) in particularwhen the
alternative cis-splice partner site of the target is weaker compared with
the ss of the trans-splicing RNA.
The chimeric RNAs generated in the course of heterologous viral
RNA trans-splicing either (1) did not lead to the translation of fusion
proteins, because (1a) multiple stop codons will only allow the forma-
tion of a truncated cellular protein such as in the case of the adenoviral
trans-splice to the v-abl proto-oncogene homolog or because (1b) the
translational start site is lost upon trans-splicing as in the case of the
Armadillo protein with the adenoviral RNA, or (2) yielded fusion pro-
teins of unknown function. Therefore, the highly transforming
100 kDa SV40 super T antigen remains the only example of a functionalracting pre-mRNAmolecule. a, A strong viral cryptic or regular 3′ acceptor ss trans-splices
onic splice donor (SDi). Ss that could compete with the trans-splicing sites for cis-splicing
ptic splice donor sites (at aa positions 66 and 74) trans-splicewith a splice acceptor site of a
ort the trans-splice reaction.Notably, in order to allow antisense binding via theBDs one of
; SD: strong donor;WA: weak acceptor; SA: strong acceptor; Cry: cryptic ss; *: ESE: exonic
Fig. 2. Selection of splice sites for RNA trans-splicing. a, Schematic illustration of the test system. HepG2 cells were co-transfected with plasmids expressing an artiﬁcial mini-gene com-
posed of 3 exons (E1–E3) and 2 introns (I1 and I2) and trans-splicing RNAs (5′-tsRNA harbouring exon E1* or 3′-tsRNA harbouring exon E3*) suitable either for 5′ or 3′ exon replacement.
The 50 nt binding domains BD1 or BD2 guide the respective trans-splicing RNAs to I1 or I2. Total RNAwas isolated 24 h after transfection and trans-splice products resulting from proximal
(dashed arrows) or distal (continuous arrows) trans-splicing were quantiﬁed using rtRT-PCR, standardised using β-actin expression levels, and relative trans-splice activities (blue) were
calculated as described under b. Proximal trans-splicing was detected using primer pairs F1*/R1 (E1*/E2) or F2/R2* (E2/E3*), distal trans-splicing using primer pairs F1*/R2 (E1*/E3) or
F1/R2* (E1/E3*). BP: branch point (5′-UACUAACA-3′); Ppy: polypyrimidine tract (5′-UUUUUUUCCCUUUUUUUCC-3′). D 5′-CAG/GUAAGU-3′, D1 5′-CAG/GUGAGU-3′, D2 5′-AAG/
GUAUCA-3′, A 5′-UUUUUUCCCUUUUUUUCCAG-3′, A1 5′-ACAUAAAAUAUUUCUUAUAG-3′, and A2 5′-UUUGUUUCCUCUACAUCUAG-3′. Splice site scores predicted with BDGP SSP soft-
ware (magenta) and ASSP software (green). b, Relative trans-splice (ts) activities for proximal (black) and distal (grey) trans-splicing. Values represent the mean± SEM of two indepen-
dent transfection experimentswith each sample run in triplicates. RelativemRNA expressionwas calculated in terms of fold change (2−ΔΔCt)whereΔCt=Cttrans-spliced− Ctβ-actin. Relative
activities for proximal trans-splicing (5′ and 3′ER) were set to 1. Signiﬁcance was tested using the one-way ANOVA test with Bonferroni correction.
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trans-splicing.
Thus, our analyses suggest that the reported cases of heterologous
viral RNA trans-splicing, unlike the homologous SV40 trans-splicing, re-
ﬂect chance events which may occur in the course of active viral RNA
transcription but which are meaningless for the involved viruses. On
the other hand, both our analyses and the frequency of reported viral
trans-splicing events emphasize the high competence of distinct viral
sequences for RNA trans-splicing. This assumption is further supported
by trans-splicing events detected between SV40 RNA and sequences of
themurine polyomavirus or adenoviruses (J Eul & V Patzel, unpublished
data). This may indicate that HIV-1, adenovirus type 5, and possibly
other viruses use the mechanism of trans-splicing in the same way as
the SV40 to diversify their sequences and gene products. One may
then address the question why trans-splicing has not yet been
observed for these viruses, though extensive cis-splicing was reported
e.g. among the transcripts of HIV-1 [11]. A plausible explanation might
be that the study design wasn't suitable to detect trans-splicing or that
researchers have not been considering potential trans-splice events.
Thus, targeted investigations to exploit viral trans-splicing might shed
light to answer this question in the future. RNA trans-splicing is increas-
ingly considered for therapeutic applications and researchers might
explore the features of highly efﬁcient viral RNA trans-splicing for the
design of therapeutic trans-splicing RNAs.
1. Methods
1.1. RNA sequences
Nucleotide sequences of the analysed RNAs were obtained from
NCBI GenBank.
1.2. Analysis of splice site strengths
The numbers of consecutive base pairs and hydrogen bonds (hb)
that can be formed between splice donor sites and the spliceosomal
U1 snRNA as well as matches, base pairs, and hydrogen bonds between
the U2 snRNA and the branch point consensus sequence, and sequence
matches with the poly U/C stretch consensus sequence were counted
manually. For the count of hydrogen bonds canonical Watson–Crick (G
≡ C = 3hb; A = U= 2hb) as well as wobble base pairs (G · U = 2hb)
were considered. Ss strengthwas further investigated using the software
Alternative Splice Site Predictor (ASSP) http://wangcomputing.com/
assp/overview.html [7]. The software provides ab initio recognition of
the probable splice sites based on the position and strength of ss, length,GC content, regulatory elements, consensus polypyrimidine tract and
branch point regions. For analysis of possible trans-splicing between
the viruses and the targets, default cut-off values of the software (2.2
for acceptor and 4.5 for donor) were considered along with the full
length RNA sequences. The tabulated result generated with the putative
ss information like position, score, GC content and conﬁdence was com-
pared with the viral sequences involved in trans-splicing. As a second
software the Berkeley Drosophila Genome Project Splice Site Prediction
(BDGP SSP), a neural network based program http://www.fruitﬂy.org/
seq_tools/splice.html [8] was used to predict the strength of splice sig-
nals at each intron/exon boundary using default cut-off values of 0.4
(range: 0–1). The software predicts the probability of the ss usage
based on the consensus motifs involved in splicing.
1.3. Analysis of purine rich splice enhancers
In the ﬁrst step, purine-rich sequences with 7 or more nts that
contain the triplets GAA, AAG, GGA, GAG or AAA (all 5′ to 3′; but no C
or T/U)were identiﬁed. Purine-rich sequenceswith these triplets are lo-
cated in nt-motifs that can bind the splice enhancer proteins ASF/SF2
(5′-GAGGAGGAG-3′), SRp40 (5′-GAGGAAGAA-3′), SRp75 (5′-GAAG
GA-3′), SC35 (5′-GAAGAAGAA-3′), Tra2α (5′-GAAGAGGAAG-3′),
Tra2β (5′-AAGAAGAAG-3′), or other unknown proteins, etc. [9] and
thus may act as putative ESEs in the viral and cellular sequences.
1.4. Analysis of dimerization domains
Complementary between trans-splicing RNA sequences was investi-
gated by sequence alignments (considering one sequence as reverse
complement) using the BLASTn software (NCBI). Possible wobble base
pairing was considered manually.
1.5. Experimental investigation of trans-splice activities
The artiﬁcial mini-gene of 3779 nts in length encompassing three
exons and two introns as well as the genes expressing two trans-
splicing RNAs for 5′ or 3′ exon replacement were generated by gene
synthesis (GeneArt, Regensburg, Germany) and subcloned into the vec-
tor pVAX1 (Invitrogen, Carlsbad, CA). HepG2 cells were co-transfected
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) with the mini-
gene plasmid and each one of the trans-splicing constructs and total
RNA was isolated 24 h post transfection using the RNeasy Plus Kit
(Qiagen, Hilden, Germany). 500 ng of RNA was reverse transcribed
using random hexamer primers and the cDNA of trans-spliced RNA
was quantiﬁed by SYBR green rtPCR using an ABI PRISM 7900HT
57S. Poddar et al. / Computational and Structural Biotechnology Journal 10 (2014) 51–57Sequence Detection System (Applied Biosystems, Foster City, CA) using
primers F1 5′-AGTCTTCAGGGTGTTTAGAAAACCA-3′, F2 5′-CATCTTGCTG
CAAAGCTGAAAA-3′, F1* 5′-CAGGCTCCATACCGACGATC-3′, R1 5′-TTCT
CATGGCAAAGTTCTTCCA-3′, R2 5′-AAGCTGCTTTCTCTTAATTCTTTTGT
AAC-3′, and R1* 5′-TTGCTGTGTCCCCGTGATC-3′ (AITbiotech,
Singapore). Relative trans-splice activities were calculated by the com-
parative Ct method (ΔΔCt) using β-actin as internal control. The indi-
cated fold change values were calculated as 2−ΔΔCt.Conﬂict of interest statement
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